About Matthew Witek
Matthew Witek, CEO and founder of Veriray, is a board-certified radiation oncologist and professor with over a decade of experience delivering advanced radiation therapy within esteemed academic institutions.
Inspiration Behind Veriray
Dr. Witek’s vision for Veriray was shaped by his work conducting radiation therapy quality assurance for large international phase III clinical trials. During these reviews, he observed:
- Significant variability in radiation therapy quality and its potential impact on trial outcomes.
- A critical gap in existing quality assurance processes, which were insufficient for biopharmaceutical companies to properly evaluate the impact of radiation therapy (RT) on clinical outcomes.
The Veriray Mission
To address these challenges, Veriray provides comprehensive RT oversight, enabling biopharmaceutical companies to:
- Accurately assess the clinical efficacy and toxicity profiles of investigational drugs.
- Make informed decisions throughout drug development.
Dr. Witek’s expertise and dedication continue to drive Veriray’s mission to empower better outcomes through advanced radiotherapy solutions.
Veriray 